Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats

Background Osimertinib, as third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment approved to treat advanced T790M mutation-positive tumors. Triazole antifungals are therapeutic drugs for cancer patients to reduce the risk of opportunistic...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Yutao Lou, Feifeng Song, Mengting Cheng, Ying Hu, Yitao Chai, Qing Hu, Qiyue Wang, Hongying Zhou, Meihua Bao, Jinping Gu, Yiwen Zhang
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	PeerJ Inc. 2023-08-01
Reeks:	PeerJ
Onderwerpen:	Osimertinib Voriconazole Itraconazole Fluconazole Pharmacokinetics HPLC-MS/MS
Online toegang:	https://peerj.com/articles/15844.pdf
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!